- Home
- VRDN vs UAA Comparison
VRDN vs UAA Comparison
Compare VRDN & UAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRDN | UAA |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2014 | 2005 |
Fundamental Metrics
Financial Performance| Metric | VRDN | UAA |
|---|---|---|
| Price | $24.57 | $4.97 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 17 | 26 |
| Target Price | ★ $36.20 | $6.30 |
| AVG Volume (30 Days) | 2.0M | ★ 7.8M |
| Earning Date | 11-04-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,706,000.00 | ★ $4,966,370,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $878.45 | $2.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.18 | $4.13 |
| 52 Week High | $34.29 | $8.15 |
Technical Indicators
Market Signals| Indicator | VRDN | UAA |
|---|---|---|
| Relative Strength Index (RSI) | 68.17 | 54.79 |
| Support Level | $21.40 | $4.81 |
| Resistance Level | $24.86 | $5.06 |
| Average True Range (ATR) | 1.00 | 0.19 |
| MACD | 0.57 | 0.03 |
| Stochastic Oscillator | 88.72 | 70.62 |
Price Performance
Historical ComparisonAbout VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
About UAA Under Armour Inc.
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 440 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.